Biocircuits to ship IOS point-of-care immunodiagnostic system in early 1996.
This article was originally published in The Gray Sheet
Executive Summary
BIOCIRCUITS' IOS POINT-OF-CARE IMMUNODIAGNOSTIC SYSTEM SHIPMENTS are expected to begin in early 1996, the company says. Cleared for marketing by FDA on Dec. 1, the physician-office/point-of-care instrument is being sold for $6,000. The intended market for the device is the approximately 45,000 small- to medium-sized physician practices that already do clinical chemistry and/or hematology testing in-house but use outside labs for immunodiagnostic testing.
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.